Gemcitabine plus cisplatin for the treatment of metastatic breast cancer

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anthracycline; Cisplatin; Gemcitabine; Salvage therapy; Taxanes; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PYRIMIDINE DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEARING LOSS; HUMAN; METASTASIS POTENTIAL; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0036072839     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.s.006     Document Type: Article

References (30)

1. Phase II study of gemcitabine in patients with metastatic breast cancer
2. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
3. Advanced breast cancer: A phase II trial with gemcitabine
4. Gemcitabine (G) in pretreated breast cancer (BC)
5. Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens
6. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer
7. Is cisplatin useful for breast cancer?
8. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer
9. Cisplatin as first-line therapy for metastatic breast cancer
10. A phase II trial of cis-dichlorodiammine platinum II in breast and ovarian carcinomas
11. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules
12. A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules
13. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: Pharmacokinetics, toxicity, and therapeutic efficacy
14. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer
15. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory treatment
16. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens
17. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines
18. Combination chemotherapy studies with gemcitabine
19. Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage
20. Phase II trial of cisplatin (CDDP) & gemcitabine (DFDC) in heavily pretreated breast cancer
21. Gemcitabine safety overview
22. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
23. Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC)
24. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: A North Central Treatment Group trial
25. A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC)
26. Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer
27. Significant activity of gemcitabine (GEM) and cisplatin (DDP) in both heavily (H) and minimally (M) pretreated metastatic breast cancer (MBC) patients: A California Cancer Consortium/Loyola Univ. Chicago Trial
28. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
29. Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: Preliminary results of a phase II study
30. Is cisplatin & gemcitabine equivalent to carboplatin & gemcitabine? Yes and no